Do analysts rate NBRV or AKAN?

Given Nabriva Therapeutics' higher probable upside, analysts plainly believe Nabriva Therapeutics is more favorable than Akanda. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, NBRV or AKAN?

Akanda has lower revenue, but higher earnings than Nabriva Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nabriva Therapeutics $35.59M 0.00 -$57.19M -$19.20 N/A Akanda $836.66K 10.21 -$4.10M N/A N/A

Do analysts recommend ATOS or AKAN?

Atossa Genetics presently has a consensus price target of $36.33, indicating a potential upside of 671.41%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities analysts clearly believe Atossa Genetics is more favorable than Akanda. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, ATOS or AKAN?

Akanda has higher revenue and earnings than Atossa Genetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atossa Genetics N/A N/A -$34.77M -$3.21 N/A Akanda $836.66K 10.21 -$4.10M N/A N/A

Is ATOS or AKAN more profitable?

Akanda's return on equity of 0.00% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -84.91% -72.36% Akanda N/A N/A N/A

Does the media favor ATOS or AKAN?

In the previous week, Akanda had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for Akanda and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.85 beat Akanda's score of 0.72 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akanda 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GRML or AKAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, GRML or AKAN?

Akanda has higher revenue and earnings than Greenland Mines Ltd. Common Stock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenland Mines Ltd. Common Stock N/A N/A -$10.55M -$0.32 N/A Akanda $836.66K 10.21 -$4.10M N/A N/A

Is GRML or AKAN more profitable?

Akanda's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Greenland Mines Ltd. Common Stock N/A -109.40% -98.80% Akanda N/A N/A N/A

Does the media prefer GRML or AKAN?

In the previous week, Greenland Mines Ltd. Common Stock and Greenland Mines Ltd. Common Stock both had 3 articles in the media. Akanda's average media sentiment score of 0.72 beat Greenland Mines Ltd. Common Stock's score of 0.63 indicating that Akanda is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenland Mines Ltd. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akanda 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer KALA or AKAN?

KALA BIO presently has a consensus price target of $1,018.75, indicating a potential upside of 44,680.22%. Given KALA BIO's stronger consensus rating and higher probable upside, research analysts clearly believe KALA BIO is more favorable than Akanda. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, KALA or AKAN?

Akanda has higher revenue and earnings than KALA BIO. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$96.14 N/A Akanda $836.66K 10.21 -$4.10M N/A N/A

Is KALA or AKAN more profitable?

Akanda's return on equity of 0.00% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% Akanda N/A N/A N/A

Do analysts rate QUCY or AKAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, QUCY or AKAN?

Akanda has higher revenue and earnings than Mainz Biomed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $537.08K 69.91 -$16.21M -$47.60 N/A Akanda $836.66K 10.21 -$4.10M N/A N/A

Is QUCY or AKAN more profitable?

Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Akanda N/A N/A N/A

Does the media favor QUCY or AKAN?

In the previous week, Mainz Biomed had 2 more articles in the media than Akanda. MarketBeat recorded 5 mentions for Mainz Biomed and 3 mentions for Akanda. Akanda's average media sentiment score of 0.72 beat Mainz Biomed's score of 0.15 indicating that Akanda is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akanda 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Akanda (AKAN) Competitors

$16.27 -0.83 (-4.85%)

As of 02:47 PM Eastern

Compare

AKAN vs. NBRV, ATOS, GRML, KALA, and QUCY

Should you buy Akanda stock or one of its competitors? MarketBeat compares Akanda with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akanda include Nabriva Therapeutics (NBRV), Atossa Genetics (ATOS), Greenland Mines Ltd. Common Stock (GRML), KALA BIO (KALA), and Mainz Biomed (QUCY). These companies are all part of the "pharmaceutical products" industry.

How does Akanda compare to Nabriva Therapeutics?

Nabriva Therapeutics (NASDAQ:NBRV) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

0.3% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by company insiders. Comparatively, 20.4% of Akanda shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Akanda has lower revenue, but higher earnings than Nabriva Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A
Akanda	$836.66K	10.21	-$4.10M	N/A	N/A

Given Nabriva Therapeutics' higher probable upside, analysts plainly believe Nabriva Therapeutics is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nabriva Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Akanda has a beta of 14.02, meaning that its stock price is 1,302% more volatile than the broader market.

In the previous week, Akanda had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 3 mentions for Akanda and 0 mentions for Nabriva Therapeutics. Akanda's average media sentiment score of 0.72 beat Nabriva Therapeutics' score of 0.00 indicating that Akanda is being referred to more favorably in the news media.

Company	Overall Sentiment
Nabriva Therapeutics	Neutral
Akanda	Positive

Akanda has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Akanda's return on equity of 0.00% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
Akanda	N/A	N/A	N/A

Summary

Akanda beats Nabriva Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Akanda compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Akanda had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for Akanda and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.85 beat Akanda's score of 0.72 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akanda	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akanda's return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
Akanda	N/A	N/A	N/A

Atossa Genetics has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Akanda has a beta of 14.02, indicating that its share price is 1,302% more volatile than the broader market.

Atossa Genetics presently has a consensus price target of $36.33, indicating a potential upside of 671.41%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities analysts clearly believe Atossa Genetics is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Akanda has higher revenue and earnings than Atossa Genetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
Akanda	$836.66K	10.21	-$4.10M	N/A	N/A

Summary

Akanda beats Atossa Genetics on 7 of the 13 factors compared between the two stocks.

How does Akanda compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Greenland Mines Ltd. Common Stock and Greenland Mines Ltd. Common Stock both had 3 articles in the media. Akanda's average media sentiment score of 0.72 beat Greenland Mines Ltd. Common Stock's score of 0.63 indicating that Akanda is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenland Mines Ltd. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akanda	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akanda has higher revenue and earnings than Greenland Mines Ltd. Common Stock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A
Akanda	$836.66K	10.21	-$4.10M	N/A	N/A

Akanda's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%
Akanda	N/A	N/A	N/A

Greenland Mines Ltd. Common Stock has a beta of 6.97, suggesting that its share price is 597% more volatile than the broader market. Comparatively, Akanda has a beta of 14.02, suggesting that its share price is 1,302% more volatile than the broader market.

20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are owned by insiders. Comparatively, 20.4% of Akanda shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Akanda beats Greenland Mines Ltd. Common Stock on 7 of the 8 factors compared between the two stocks.

How does Akanda compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Akanda's return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
Akanda	N/A	N/A	N/A

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 20.4% of Akanda shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Akanda has higher revenue and earnings than KALA BIO.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
Akanda	$836.66K	10.21	-$4.10M	N/A	N/A

KALA BIO has a beta of -2.4, indicating that its share price is 340% less volatile than the broader market. Comparatively, Akanda has a beta of 14.02, indicating that its share price is 1,302% more volatile than the broader market.

KALA BIO presently has a consensus price target of $1,018.75, indicating a potential upside of 44,680.22%. Given KALA BIO's stronger consensus rating and higher probable upside, research analysts clearly believe KALA BIO is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Akanda had 1 more articles in the media than KALA BIO. MarketBeat recorded 3 mentions for Akanda and 2 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.44 beat Akanda's score of 0.72 indicating that KALA BIO is being referred to more favorably in the media.

Company	Overall Sentiment
KALA BIO	Positive
Akanda	Positive

Summary

Akanda beats KALA BIO on 7 of the 12 factors compared between the two stocks.

How does Akanda compare to Mainz Biomed?

Mainz Biomed (NASDAQ:QUCY) and Akanda (NASDAQ:AKAN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Mainz Biomed had 2 more articles in the media than Akanda. MarketBeat recorded 5 mentions for Mainz Biomed and 3 mentions for Akanda. Akanda's average media sentiment score of 0.72 beat Mainz Biomed's score of 0.15 indicating that Akanda is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akanda	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.0% of Akanda shares are held by institutional investors. 9.8% of Mainz Biomed shares are held by insiders. Comparatively, 20.4% of Akanda shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Akanda has higher revenue and earnings than Mainz Biomed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$537.08K	69.91	-$16.21M	-$47.60	N/A
Akanda	$836.66K	10.21	-$4.10M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Akanda	N/A	N/A	N/A

Mainz Biomed has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market. Comparatively, Akanda has a beta of 14.02, indicating that its stock price is 1,302% more volatile than the broader market.

Summary

Akanda beats Mainz Biomed on 6 of the 9 factors compared between the two stocks.

Get Akanda News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKAN vs. The Competition

Export

Metric	Akanda	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.54M	$7.85B	$6.26B	$12.43B
Dividend Yield	N/A	2.56%	2.69%	5.29%
P/E Ratio	N/A	15.36	22.42	24.23
Price / Sales	10.21	5.66	548.01	125.38
Price / Cash	N/A	17.23	42.31	57.88
Price / Book	0.08	3.53	9.82	6.71
Net Income	-$4.10M	$224.05M	$3.56B	$337.09M
7 Day Performance	-24.92%	-1.22%	-1.17%	0.63%
1 Month Performance	-71.50%	0.23%	3.71%	5.15%
1 Year Performance	-81.64%	-0.04%	27.28%	34.36%

Akanda Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKAN Akanda	0.8061 of 5 stars	$16.27 -4.9%	N/A	-79.4%	$8.54M	$836.66K	N/A	110	Gap Down
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70
ATOS Atossa Genetics	2.4265 of 5 stars	$5.12 +3.4%	$36.33 +609.6%	-62.7%	$44.08M	N/A	N/A	8
GRML Greenland Mines Ltd. Common Stock	0.8609 of 5 stars	$0.36 +0.2%	N/A	+94.1%	$43.72M	N/A	N/A	5	News Coverage
KALA KALA BIO	3.0756 of 5 stars	$2.33 +7.4%	$1,018.75 +43,623.2%	-98.6%	$43.32M	N/A	N/A	30	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKAN) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akanda (AKAN) Competitors

AKAN vs. NBRV, ATOS, GRML, KALA, and QUCY

How does Akanda compare to Nabriva Therapeutics?

Summary

How does Akanda compare to Atossa Genetics?

Summary

How does Akanda compare to Greenland Mines Ltd. Common Stock?

Summary

How does Akanda compare to KALA BIO?

Summary

How does Akanda compare to Mainz Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKAN vs. The Competition

Akanda Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akanda (AKAN) Competitors

AKAN vs. NBRV, ATOS, GRML, KALA, and QUCY

How does Akanda compare to Nabriva Therapeutics?

Do institutionals & insiders have more ownership in NBRV or AKAN?

Which has better earnings and valuation, NBRV or AKAN?

Do analysts rate NBRV or AKAN?

Which has more risk and volatility, NBRV or AKAN?

Does the media favor NBRV or AKAN?

Is NBRV or AKAN more profitable?

Summary

How does Akanda compare to Atossa Genetics?

Does the media favor ATOS or AKAN?

Is ATOS or AKAN more profitable?

Which has more volatility and risk, ATOS or AKAN?

Do analysts recommend ATOS or AKAN?

Do insiders and institutionals have more ownership in ATOS or AKAN?

Which has higher earnings and valuation, ATOS or AKAN?

Summary

How does Akanda compare to Greenland Mines Ltd. Common Stock?

Do analysts rate GRML or AKAN?

Does the media prefer GRML or AKAN?

Which has preferable earnings & valuation, GRML or AKAN?

Is GRML or AKAN more profitable?

Which has more volatility and risk, GRML or AKAN?

Do insiders & institutionals hold more shares of GRML or AKAN?

Summary

How does Akanda compare to KALA BIO?

Is KALA or AKAN more profitable?

Do insiders and institutionals believe in KALA or AKAN?

Which has higher valuation and earnings, KALA or AKAN?

Which has more risk and volatility, KALA or AKAN?

Do analysts prefer KALA or AKAN?

Does the media prefer KALA or AKAN?

Summary

How does Akanda compare to Mainz Biomed?

Do analysts rate QUCY or AKAN?

Does the media favor QUCY or AKAN?

Do institutionals and insiders believe in QUCY or AKAN?

Which has stronger earnings and valuation, QUCY or AKAN?

Is QUCY or AKAN more profitable?

Which has more volatility & risk, QUCY or AKAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKAN vs. The Competition

Akanda Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools